Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

1 Jul 2020

Abstract excerpt

Abstract: In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid...

Source

Identifiers

PMID: 32802465
DOI: 10.21037/jtd.2020.01.19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal settingPMID 32802465Read ↗

Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.Semantic proximity Read ↗

Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance.Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

Somatic Mutation Profiling by NGS-Based Liquid Biopsy in Advanced Non- Small Cell Lung Cancer: Frequency, Clinical Correlates, and Prognostic SignificanceSemantic proximity Read ↗

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.Semantic proximity Read ↗

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.Semantic proximity Read ↗

Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland.Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.